These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 2116315)

  • 21. Hepatic synthesis and clearance of components of the fibrinolytic system in healthy volunteers and in patients with different stages of liver cirrhosis.
    Huber K; Kirchheimer JC; Korninger C; Binder BR
    Thromb Res; 1991 Jun; 62(5):491-500. PubMed ID: 1910213
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polycythemia Vera.
    Spivak JL
    Curr Treat Options Oncol; 2018 Mar; 19(2):12. PubMed ID: 29516275
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
    Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
    Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A specific immunologic assay for functional plasminogen activator inhibitor 1 in plasma--standardized measurements of the inhibitor and related parameters in patients with venous thromboembolic disease.
    Philips M; Juul AG; Selmer J; Lind B; Thorsen S
    Thromb Haemost; 1992 Nov; 68(5):486-94. PubMed ID: 1455392
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fibrinogen, t-PA, and PAI-1 plasma levels in patients with pulmonary hypertension.
    Huber K; Beckmann R; Frank H; Kneussl M; Mlczoch J; Binder BR
    Am J Respir Crit Care Med; 1994 Oct; 150(4):929-33. PubMed ID: 7921465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nitric oxide scavenging by cell-free hemoglobin may be a primary factor determining hypertension in polycythemic patients.
    Rusak T; Misztal T; Piszcz J; Tomasiak M
    Free Radic Res; 2014 Feb; 48(2):230-8. PubMed ID: 24180690
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Decreased fibrinolytic capacity in coronary patients by increased plasminogen activator inhibitor activity].
    Ihnken K; Speiser W; Müller-Berghaus G; Beyersdorf F; Schlepper M; Satter P
    Helv Chir Acta; 1992 Jan; 58(4):503-8. PubMed ID: 1582860
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inapparent polycythemia vera: an unrecognized diagnosis.
    Lamy T; Devillers A; Bernard M; Moisan A; Grulois I; Drenou B; Amiot L; Fauchet R; Le Prise PY
    Am J Med; 1997 Jan; 102(1):14-20. PubMed ID: 9209196
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tissue plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1) in diabetic foot syndrome.
    Kulwas A; Lisewska B; Jundziłł W; Ruszkowska B; Drewniak W; Ruprecht Z; Gadomska G; Rość D
    Adv Med Sci; 2017 Mar; 62(1):87-91. PubMed ID: 28193577
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination.
    Nagayama M; Sato A; Hayakawa H; Urano T; Takada Y; Takada A
    Cancer; 1994 Mar; 73(5):1398-405. PubMed ID: 8111706
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1).
    Angleton P; Chandler WL; Schmer G
    Circulation; 1989 Jan; 79(1):101-6. PubMed ID: 2491971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduced in vitro clot lysis and release of more active platelet PAI-1 in polycythemia vera and essential thrombocythemia.
    Pósán E; Ujj G; Kiss A; Telek B; Rák K; Udvardy M
    Thromb Res; 1998 Apr; 90(2):51-6. PubMed ID: 9684757
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Depression of tissue-type plasminogen activator and enhancement of urokinase-type plasminogen activator as an expression of local inflammation.
    Brommer EJ; Dooijewaard G; Dijkmans BA; Breedveld FC
    Thromb Haemost; 1992 Aug; 68(2):180-4. PubMed ID: 1412164
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of dextran on plasma tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1) during surgery.
    Eriksson M; Saldeen T
    Acta Anaesthesiol Scand; 1995 Feb; 39(2):163-6. PubMed ID: 7540788
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypocholesterolemia in patients with polycythemia vera.
    Fujita H; Hamaki T; Handa N; Ohwada A; Tomiyama J; Nishimura S
    J Clin Exp Hematop; 2012; 52(2):85-9. PubMed ID: 23037623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Quantity and rate of erythrocyte sedimentation in polycythemia vera and symptomatic erythrocytosis].
    Shulaeva EV; Shupik EI; Gritsenko LA
    Vrach Delo; 1978 Dec; (12):54-6. PubMed ID: 741725
    [No Abstract]   [Full Text] [Related]  

  • 37. Levels of fibrinolytic activators and inhibitors in plasma after severe trauma.
    Sørensen JV
    Blood Coagul Fibrinolysis; 1994 Feb; 5(1):43-9. PubMed ID: 7514044
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1) in children with ulcerative colitis].
    Grabarczyk E; Szaflarska-Popławska A; Góralczyk K; Rość D
    Pol Merkur Lekarski; 2006 Mar; 20(117):326-8. PubMed ID: 16780267
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Red cell mass measurement in patients with clinically suspected diagnosis of polycythemia vera or essential thrombocythemia.
    Alvarez-Larrán A; Ancochea A; Angona A; Pedro C; García-Pallarols F; Martínez-Avilés L; Bellosillo B; Besses C
    Haematologica; 2012 Nov; 97(11):1704-7. PubMed ID: 22689671
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma erythropoietin in polycythemia.
    Erslev AJ; Caro J; Kansu E; Miller O; Cobbs E
    Am J Med; 1979 Feb; 66(2):243-7. PubMed ID: 425968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.